Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CONTROVERSIES IN THE MANAGEMENT OF OVARIAN-CANCER
Autore:
OZOLS RF;
Indirizzi:
FOX CHASE CANC CTR,7701 BURHOLME AVE PHILADELPHIA PA 19111
Titolo Testata:
International journal of gynecological cancer
, volume: 7, anno: 1997, supplemento:, 1
pagine: 27 - 32
SICI:
1048-891X(1997)7:<27:CITMOO>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
GYNECOLOGIC-ONCOLOGY-GROUP; CYTOREDUCTIVE SURGERY; CHEMOTHERAPY; CARCINOMA; THERAPY; CARBOPLATIN; PACLITAXEL; PROGNOSIS; TAMOXIFEN; SUPPORT;
Keywords:
CISPLATIN-CYCLOPHOSPHAMIDE; CYTOREDUCTIVE SURGERY; DOSE INTENSITY; INTRAPERITONEAL CHEMOTHERAPY; NEW STANDARD CHEMOTHERAPY; PACLITAXEL-CISPLATIN; WHOLE ABDOMEN IRRADIATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
29
Recensione:
Indirizzi per estratti:
Citazione:
R.F. Ozols, "CONTROVERSIES IN THE MANAGEMENT OF OVARIAN-CANCER", International journal of gynecological cancer, 7, 1997, pp. 27-32

Abstract

A new standard chemotherapy for ovarian cancer has been accepted in the USA: paclitaxel (Taxol(R)) plus a platinum compound (cisplatin or carboplatin). There remain, however, many areas of controversy in treating this disease, including the role of cytoreductive surgery, the optimum combination regimen, the approach to managing patients who achieve a clinical remission, the importance of dose intensity in chemotherapy, the efficacy of intraperitoneal therapy, the benefit of whole-abdomen irradiation, and the status of immunotherapy and hormones.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/08/20 alle ore 16:59:01